105611-92-5

Basic information

• Product Name: 3-[(METHYLSULFONYL)AMINO]PROPANOIC ACID
• Synonyms: 3-[(METHYLSULFONYL)AMINO]PROPANOIC ACID;beta-alanine, N-(methylsulfonyl)-;N-(methylsulfonyl)-beta-alanine;N-(methylsulfonyl)-beta-alanine(SALTDATA: FREE);3-methanesulfonamidopropanoic acid;3-methanesulfonamidopropionic acid;3-Methanesulfonylamino-propionic acid;ASN 15420960
• CAS NO: 105611-92-5
• Molecular Formula: C₄H₉NO₄S
• Molecular Weight: 167.18
• Mol File: 105611-92-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-[(METHYLSULFONYL)AMINO]PROPANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(METHYLSULFONYL)AMINO]PROPANOIC ACID(105611-92-5)
• EPA Substance Registry System: 3-[(METHYLSULFONYL)AMINO]PROPANOIC ACID(105611-92-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 105611-92-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
3-[(METHYLSULFONYL)AMINO]PROPANOIC ACID is used as a therapeutic agent for its potential to treat various medical conditions, such as liver damage and inflammatory bowel disease. Its anti-inflammatory and antioxidant properties contribute to its potential efficacy in these areas.
Used in Cosmetic and Skincare Applications:
3-[(METHYLSULFONYL)AMINO]PROPANOIC ACID is used as a skin-soothing and calming ingredient in cosmetic and skincare products. Its potential to provide soothing and calming effects on the skin makes it a valuable component in formulations aimed at reducing inflammation and promoting skin health.

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 107-95-9 3-amino propanoic acid 

Relevant articles and documents

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib

Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with BRCA mutations. Here, we exploit a new paradigm based on the possibility of triggering synthetic lethality using only small organic molecules (dubbed "fully small-molecule-induced synthetic lethality"). We exploited this paradigm to target pancreatic cancer, one of the major unmet needs in oncology. We discovered a dihydroquinolone pyrazoline-based molecule (35d) that disrupts the RAD51-BRCA2 protein-protein interaction, thus mimicking the effect of BRCA2 mutation. 35d inhibits the homologous recombination in a human pancreatic adenocarcinoma cell line. In addition, it synergizes with olaparib (a PARPi) to trigger synthetic lethality. This strategy aims to widen the use of PARPi in BRCA-competent and olaparib-resistant cancers, making fully small-molecule-induced synthetic lethality an innovative approach toward unmet oncological needs.

Novel peptides which are active on the central nervous system and have an action on the cholinergic system

The invention relates to peptides of the formula I in which R4 denotes an acyl group, R5 denotes D-Lys or Lys, A6 denotes the radical of phenylalanine, N-methylphenylalanine, 4- alkoxyphenylalanine or 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, and R7 denotes a basic radical, processes for their preparation and their use.